A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-07-19
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-28 (study day 27); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 140); relationship: Y
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-03-30 (study day 241); relationship: not assessed
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-05 (study day 369); relationship: Y
Data queries
No data queries.